[Skip to Content]
[Skip to Content Landing]
Article
December 1972

Diphenylhydantoin and an Insulin-Secreting Islet Adenoma

Author Affiliations

Chicago

From the Section of Endocrinology and Metabolism, Department of Medicine, Northwestern University-McGaw Medical Center, Chicago. Dr. Knopp is now with the Thorndike Memorial Laboratory, Boston City Hospital, Boston.

Arch Intern Med. 1972;130(6):904-908. doi:10.1001/archinte.1972.03650060094017
Abstract

The diagnosis of an insulin-secreting islet cell adenoma was obscured in a patient treated with diphenylhydantoin sodium. Comparison of insulin responses to glucagon, tolbutamide, and leucine before and after drug withdrawal indicated that the diphenylhydantoin was inhibiting "stimulated" insulin release from the tumor. Another clue to hyperinsulinism was the restraint of hepatic ketogenesis and urinary nitrogen excretion during fasting. Diphenylhydantoin, or an analogue, may deserve further trial as adjunctive therapy in the control of insulinoma-induced hypoglycemia.

×